國家衛生研究院 NHRI:Item 3990099045/6137
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 925091      線上人數 : 915
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於NHRI管理 到手機版
    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6137


    題名: Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001-2006
    作者: Tang, ST;Liu, TW;Chang, WC;Wang, HM;Chen, JS;Koong, SL;Hsiao, SC
    貢獻者: National Institute of Cancer Research
    摘要: Background: The availability of new chemotherapeutic agents has lengthened the treatment timeline for advanced cancers and increases the likelihood of receiving chemotherapy near death. However, use of chemotherapy near the end of life may not benefit cancer patients, as evident by its precipitating emergency room visits, increasing intensive care unit care, precluding early hospice referral, highly frequent deaths in a hospital, elevated anxiety and depression, and a trend toward less satisfaction with care. Purpose of study: To assess the association between continuation of chemotherapy in the last month of life and patient demographics, disease characteristics, primary physician’s specialty, hospital characteristics, and healthcare resource availability at the hospital and regional levels. Methods: Retrospective population-based cohort study using administrative data among 204,850 Taiwanese cancer decedents in 2001–2006. Multivariate logistic regression was conducted to identify determinants of use of chemotherapy in the last month of life using the generalized estimating equation (GEE) method with robust standard errors accounting for correlation in the error term due to clustering of individuals in the same hospital. Results: Rates of continued chemotherapy in the last month of life for each study year were 17.5%, 17.4%, 17.3%, 19.0%, 20.0%, and 21.0%, respectively and have remained steady since 2001. Taiwanese cancer patients had greater propensity for continuation of chemotherapy in the last month of life if they were male (adjusted odds ratio [AOR]: 1.19, 95% confidence interval [CI]: 1.13–1.25), younger, single (1.21 [1.09–1.35]), had lower comorbidity levels, were diagnosed with hematologic malignancies (1.90 [1.09–1.35]) and breast cancer (1.24 [1.08–1.43]), had metastatic disease (1.36 [1.27–1.46]), and survived <1 year but longer than 2 months post-diagnosis. The propensity for continued chemotherapy in patients’ last month was significantly increased by being cared for by a medical oncologist (3.49 [3.04–3.99]) or in a teaching hospital (1.39 [1.11–1.74]) and with the highest intensity of total inpatient hospital beds (1.63 [0.99–2.68]) but was not influenced by regional healthcare resources (total hospital and hospice beds). Conclusion: The propensity to continue chemotherapy in the last month of life was determined by patient demographics and disease characteristics, physician specialty, and healthcare resources at the primary hospital level. Maintaining a delicate balance between deciding to continue chemotherapy and starting palliative care remains a challenge. However, appropriate discussion of transition from curative to palliative care may minimize the over-estimated effectiveness of chemotherapy to achieve end-of-life care that best meets cancer patients’ needs and preferences.
    日期: 2011-09
    關聯: European Journal of Cancer. 2011 Sep;47(Suppl 1):S229-S230.
    Link to: http://dx.doi.org/10.1016/S0959-8049(11)71098-X
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0959-8049&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000295752800792
    顯示於類別:[劉滄梧] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000295752800792.pdf57KbAdobe PDF632檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋